{
    "nct_id": "NCT05079919",
    "official_title": "A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients With Severe Hypertriglyceridemia",
    "inclusion_criteria": "* Fasting TG ≥ 500 mg/dL (5.65 mmol/L) at Screening and Qualification\n* Patients must be on lipid-lowering therapy that should adhere to standard of care (SOC) per local guidelines. Lipid-lowering medications should be optimized and stabilized for at least 4 weeks prior to Screening to minimize changes in these medications during the study.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Hemoglobin A1c (HbA1c) ≥ 9.5% at Screening\n* Alanine aminotransferase or aspartate aminotransferase > 3.0 × upper limit of normal\n* Total bilirubin > upper limit of normal unless due to Gilbert's syndrome\n* Estimated GFR < 30 mL/min/1.73 m^2",
    "miscellaneous_criteria": "Key"
}